FindTrial
Sign In

Clinical and biochemical profile of AKI in patients with COVID 19. A single center experience.

Correlation of clinical and biochemical profile of AKI in patients with COVID 19. A single center experience. - COVIDAKI

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/03/032067
Enrollment
800
Registered
2021-03-17
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: B338- Other specified viral diseases

Interventions

None listed

Sponsors

Departmental Funds Depaartment of Medicine SMCW Lavale Pune
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a. All adult patients (age more than 18 years) b. Diagnosed patients with COVID 19 RT-PCR positivity hospitalized in SUHRC and SMCW, Lavale, Pune.

Exclusion criteria

Exclusion criteria: a. Pediatric age group (age less than 18 years)

Design outcomes

Primary

MeasureTime frame
a. Occurrence of AKI and related complications in patients admitted with COVID 19. b. Occurrence of AKI in COVID 19 patients with rise or fall of other parameters of disease activity like, serum ferritin, CRP, LDH, IL 6.Timepoint: a. At base line b. At 48 hours c. At 7 days d. At 15 days—

Secondary

MeasureTime frame
Occurrence of and severity of complications (dialysis, hypoxia, thromboembolism, death) in COVID 19 patients.Timepoint: 14 days—

Countries

India

Contacts

Public ContactDr Girish Vasudeo Kumthekar

Symbiosis Medical College for Women and symbiosis University Hospital and Research Center

girish.kumthekar@suhrc.siu.edu.in7032295272

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026